How Technology and Care Standards Shape Outcomes in Type 1 Diabetes: Lessons from Polish and Ukrainian Children

Researchers in Poland compared how Type 1 diabetes is managed in two groups of school-aged children: 70 Polish children and 35 Ukrainian children who came to Poland as refugees starting in 2022. Both groups were matched by age, sex, and how long they'd had diabetes. The goal was to see whether differences in available tools and treatment approaches led to different outcomes.

Type 1 diabetes requires insulin every day for life. But the way insulin is given—and how closely blood sugar is monitored—can differ widely. The study looked at whether children used older insulin injection methods or newer technologies like insulin pumps and continuous glucose monitors.

Polish children used advanced diabetes technology much more often than Ukrainian children did at the start of the study. Specifically, more Polish children used continuous subcutaneous insulin infusion (CSII)—a wearable pump that delivers insulin—and continuous glucose monitoring (CGM), which tracks blood sugar levels in real time.

This difference in technology use correlated with better blood sugar control. Polish children had lower HbA1c levels, a key measure of average blood sugar control over time. Notably, this advantage held true whether children used pumps, CGM systems, or both. The data suggests that access to these tools matters for achieving better diabetes control.

The study also measured physical development by looking at height and body mass index (BMI) in both groups. Ukrainian children were shorter relative to age-matched peers than Polish children were. Ukrainian children also had lower BMI measurements, especially those whose insulin doses stayed the same over time.

When Ukrainian children stayed in Poland for a year and began using more advanced technology—more of them adopted pumps and CGM systems—their physical development improved. Height measurements increased, and BMI measurements rose toward healthier ranges. However, better blood sugar control didn't automatically follow during that first year, suggesting that growth and metabolic control respond on different timelines.

The study found that vitamin D deficiency and autoimmune thyroiditis (inflammation of the thyroid gland) were common in both groups of children with Type 1 diabetes. These comorbidities—conditions that occur alongside the main diagnosis—are important because they can affect overall health and how well children feel.

Finding these conditions early and managing them as part of routine diabetes care may help improve quality of life and prevent complications. Families and doctors should be alert to signs of thyroid problems and monitor vitamin D levels, especially in children with newly diagnosed Type 1 diabetes.

This research highlights how much access to modern diabetes technology can influence outcomes. When care standards differ between countries—or when families move from one healthcare system to another—it can affect blood sugar control, growth, and overall well-being.

While the study doesn't tell us which specific technology works best for each child, it does show that having options matters. Families and healthcare teams should work together to find the tools and approaches that fit each child's needs and life. At the same time, further research is needed to understand why physical development improved faster than blood sugar control when Ukrainian children gained access to new technology.

Source: Pediatric endocrinology, diabetes, and metabolism. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.